Literature DB >> 12429812

Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis.

Eberhard Korsching1, Jens Packeisen, Konstantin Agelopoulos, Martin Eisenacher, Reinhard Voss, Jorma Isola, Paul J van Diest, Burkhard Brandt, Werner Boecker, Horst Buerger.   

Abstract

The introduction of a concept proposing multiple cellular subgroups in the normal female breast, including cytokeratin 5/6 (Ck 5/6)-positive progenitor cells, offers a new explanation for the existence of highly aggressive breast cancers with and without Ck 5/6 expression. Using the tissue microarray technique, 166 breast cancer cases, all characterized by comparative genomic hybridization, were evaluated by immunohistochemistry, using 15 different antibodies (estrogen receptor, progesterone receptor, p53, Ki-67, c-erbB2, epidermal growth factor receptor, cyclins A, D1, and E, bcl-2, p21, p27, Ck 5/6, Ck 8/18, and smooth muscle actin) and chromogenic in situ hybridization for c-erbB2. Biomathematical cluster analysis was applied to confirm the conventional interpretation of the results by an independent approach. Ck 5/6-positive breast carcinomas were in general negative for estrogen receptor and progesterone receptor, were highly proliferating (as reflected by Ki67 and cyclin A), and were associated with specific protein expression patterns, such as expression of p53 and epithelial growth factor receptor (all related to more aggressive tumor behavior), which could further be demonstrated by biomathematical cluster analysis. In contrast Ck 5/6-negative breast carcinomas revealed a lower tumor proliferation rate, an increased expression of p21, p27, c-erbB2, and bcl-2, and a significantly lower number of genetic alterations, with losses of chromosomal material of 16q as the most common genetic alteration. Our data give the first hints to the hypothesis that different cellular subgroups in the female breast give rise to subgroups of breast carcinomas with differing protein expression and cytogenetic alteration patterns that may be related to clinical behavior.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429812     DOI: 10.1097/01.lab.0000038508.86221.b3

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  58 in total

Review 1.  Demystified...tissue microarray technology.

Authors:  J Packeisen; E Korsching; H Herbst; W Boecker; H Buerger
Journal:  Mol Pathol       Date:  2003-08

2.  Novel bright field molecular morphology methods for detection of HER2 gene amplification.

Authors:  Raymond Tubbs; James Pettay; David Hicks; Marek Skacel; Richard Powell; Tom Grogan; James Hainfeld
Journal:  J Mol Histol       Date:  2004-08       Impact factor: 2.611

Review 3.  Triple-negative breast cancer: disease entity or title of convenience?

Authors:  Lisa Carey; Eric Winer; Giuseppe Viale; David Cameron; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2010-09-28       Impact factor: 66.675

4.  Advances in cancer tissue microarray technology: Towards improved understanding and diagnostics.

Authors:  Wenjin Chen; David J Foran
Journal:  Anal Chim Acta       Date:  2006-01-23       Impact factor: 6.558

5.  [Early loss of heterozygosity on chromosome arm 16q in flat epithelial atypia of the breast. Detection by microsatellite analyses].

Authors:  H Schmidt; C Dahrenmöller; K Agelepoulos; D Hungermann; W Böcker
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

6.  Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer.

Authors:  Mevlude Inanc; Metin Ozkan; Halit Karaca; Veli Berk; Oktay Bozkurt; Ayse Ocak Duran; Ersin Ozaslan; Hulya Akgun; Fatos Tekelioglu; Ferhan Elmali
Journal:  Med Oncol       Date:  2013-12-11       Impact factor: 3.064

7.  N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.

Authors:  Jennifer A Crozier; Pooja P Advani; Betsy LaPlant; Timothy Hobday; Anthony J Jaslowski; Alvaro Moreno-Aspitia; Edith A Perez
Journal:  Clin Breast Cancer       Date:  2015-08-19       Impact factor: 3.225

8.  Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.

Authors:  Lisa D Volk-Draper; Sandeep Rajput; Kelly L Hall; Andrew Wilber; Sophia Ran
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

9.  Chromosomal changes in aggressive breast cancers with basal-like features.

Authors:  Wayne Yu; Yasmine Kanaan; Young Kyung Bae; Young-Kyung Baed; Edward Gabrielson
Journal:  Cancer Genet Cytogenet       Date:  2009-08

Review 10.  Understanding and treating triple-negative breast cancer.

Authors:  Carey Anders; Lisa A Carey
Journal:  Oncology (Williston Park)       Date:  2008-10       Impact factor: 2.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.